Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PAHC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPhibro Animal Health expands revolving credit facility by $125M to $435M
Filed April 30, 2026 · Period ending April 28, 2026 · ~1 min read
Key Changes
-
medium
Phibro increased its revolving credit commitment from $310M to $435M through Amendment No. 1 with Rabobank, adding $125M in borrowing capacity for operations, acquisitions, or other corporate purposes.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
The amendment modifies the credit agreement dated July 3, 2024. Pricing, covenants, and other material terms beyond the commitment increase are not disclosed in the filing.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
Summary
Phibro Animal Health expanded its revolving credit facility by $125 million, bringing total commitments to $435 million under an amendment executed April 28, 2026 with Rabobank as administrative agent. The upsizing provides the company with additional financial flexibility for working capital, potential acquisitions, or other corporate needs.
The filing does not disclose pricing, covenant changes, or other amended terms, so the cost and conditions of the expanded facility cannot be assessed. For a specialty animal health company, increased borrowing capacity can support growth initiatives or provide a cushion against operational volatility, though the absence of disclosed terms limits visibility into whether the expansion reflects opportunistic refinancing or a response to tighter liquidity needs.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 28, 2026, Phibro Animal Health Corporation (the “Company”) entered into Amendment No. 1 to its Credit Agreement (“Amendment No. 1”) with Coöperatieve Rabobank U.A., New York Branch, as administrative agent, collateral agent and L/C issuer, and each lender from time to time party thereto, which amends the Credit Agreement, dated as of July 3, 2024
The company entered into Amendment No. 1 to its existing credit agreement originally dated July 3, 2024. The amendment modifies the terms of the revolving credit facility with Rabobank serving as administrative agent, collateral agent, and letter of credit issuer. The filing does not disclose changes to interest rates, covenants, or other material terms beyond the commitment increase.
Event · Item 2.03 — Creation of a Direct Financial Obligation
Item 2.03 — Creation of a Direct Financial Obligation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
on April 28, 2026, the Company entered into Amendment No. 1, which increased the revolving credit commitment under the Original Credit Agreement.
Phibro Animal Health executed Amendment No. 1 to its existing credit agreement, increasing the size of its revolving credit facility. The filing does not disclose the prior commitment amount, the new commitment amount, or other amended terms such as pricing or maturity.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 10, 2026 · How we verify